<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> insufficiently controlled on <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: In this 28-day, randomized, open-label, parallel-group, multicentre study (NCT01175473), patients (mean HbA1c 7.3%) received subcutaneous lixisenatide QD (10 µg weeks 1-2, then 20 µg; n = 77) or liraglutide QD (0.6 mg week 1, 1.2 mg week 2, then 1.8 mg; n = 71) 30 min before breakfast </plain></SENT>
<SENT sid="2" pm="."><plain>Primary endpoint was change in postprandial plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (<z:chebi fb="73" ids="53262">PPG</z:chebi>) exposure from baseline to day 28 during a breakfast test meal </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Lixisenatide reduced <z:chebi fb="73" ids="53262">PPG</z:chebi> significantly more than liraglutide [mean change in AUC(0) (:30-4:30h) : -12.6 vs. -4.0 h/mmol/l, respectively; p &lt; 0.0001 (0:30 h = start of meal)] </plain></SENT>
<SENT sid="4" pm="."><plain>Change in maximum <z:chebi fb="73" ids="53262">PPG</z:chebi> excursion was -3.9 mmol/l vs. -1.4 mmol/l, respectively (p &lt; 0.0001) </plain></SENT>
<SENT sid="5" pm="."><plain>More lixisenatide-treated patients achieved 2-h <z:chebi fb="73" ids="53262">PPG</z:chebi> &lt;7.8 mmol/l (69% vs. 29%) </plain></SENT>
<SENT sid="6" pm="."><plain>Changes in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> were greater with liraglutide (-0.3 vs. -1.3 mmol/l, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Lixisenatide provided greater decreases in postprandial glucagon (p &lt; 0.05), insulin (p &lt; 0.0001) and C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (p &lt; 0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>Mean HbA1c decreased in both treatment groups (from 7.2% to 6.9% with lixisenatide vs. 7.4% to 6.9% with liraglutide) as did body weight (-1.6 kg vs. -2.4 kg, respectively) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall incidence of adverse events was lower with lixisenatide (55%) versus liraglutide (65%), with no serious events or <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> reported </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Once daily prebreakfast lixisenatide provided a significantly greater reduction in <z:chebi fb="73" ids="53262">PPG</z:chebi> (AUC) during a morning test meal versus prebreakfast liraglutide </plain></SENT>
<SENT sid="11" pm="."><plain>Lixisenatide provided significant decreases in postprandial insulin, C-<z:chebi fb="7" ids="16670">peptide</z:chebi> (vs. an increase with liraglutide) and glucagon, and better gastrointestinal tolerability than liraglutide </plain></SENT>
</text></document>